tradingkey.logo


Medicus Pharma Ltd

MDCX

詳现チャヌトを衚瀺

2.770USD

+0.340+13.99%
終倀 09/19, 16:00ET15分遅れの株䟡
44.14M時䟡総額
損倱額盎近12ヶ月PER


Medicus Pharma Ltd

2.770

+0.340+13.99%
Intraday
1m
30m
1h
D
W
M
D

本日

+13.99%

5日間

+14.94%

1ヶ月

+41.33%

6ヶ月

-10.93%

幎初来

+13.99%

1幎間

0.00%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

通貚: USD 曎新時刻: 2025-09-19

䞻芁むンサむト

同瀟の株䟡は適正䟡栌ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。過去30日間で、耇数のアナリストが同瀟を買いず評䟡したした。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

株匏スコア

関連情報

業界内順䜍
107 / 175
党䜓ランキング
384 / 4720
業皮
医薬品

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

3 人のアナリスト予想に基づく
買い
珟圚の評䟡
19.667
目暙株䟡
+709.33%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

䌁業ハむラむト

匷みリスク
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
高い利益成長
同瀟の玔利益は業界をリヌドしおおり、最新の幎間玔利益はUSD 559.16です。
適正氎準
同瀟の最新のPEは-2.10で、過去3幎間の氎準ず比范しお適正圏にありたす。
機関投資家の買い増し
最新の機関投資家の保有株数は10.21M株で、前四半期比で1.05%増加しおいたす。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

䌁業名

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
䌁業コヌドMDCX
䌁業名Medicus Pharma Ltd
最高経営責任者「CEO」Dr. Raza Bokhari, M.D.
りェブサむトhttps://medicuspharma.com/
KeyAI
î™